01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
23:37 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor...
17:33 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

IPH4102: Preliminary Ph I data

Preliminary data from 16 evaluable patients with KIR3dL2-positive, relapsed or refractory CTCL in the dose-escalation portion of the open-label, international Phase I IPH4102-101 trial showed that 0.0001-1.5 mg/kg doses of IV IPH4102 were well tolerated...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

IPH4102: Phase I started

Innate began an open-label, international Phase I trial of IV IPH4102 in about 60 patients with KIR3dL 2-positive CTCL who received >=2 prior lines of therapy. The dose-escalation portion will evaluate 10 dose levels in...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cutaneous T cell lymphoma (CTCL) Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K) Studies in mice and patient samples suggest an...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

IPH4102 regulatory update

The European Commission granted Orphan Drug designation to IPH4102 to treat cutaneous T cell lymphoma (CTCL). Next year, Innate plans to begin a Phase I trial with the humanized mAb against killer cell immunoglobulin-like receptor...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; CD158E1); KIR3DL2 (CD158K); KIR3DL3 (CD158Z); CD20 In vitro and mouse studies suggest combining...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Innate Pharma preclinical data

In mouse xenograft models of lymphoma, twice-weekly 300 µg injections of 1 of 2 IPH41 mAbs significantly increased median survival vs. IgG1-treated controls. Data were presented at the American Association for Cancer Research meeting in...